Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 83, Issue 4, 1999, Pages 311-317

  Meltzer, Eli O ^a   Casale, Thomas B ^b   Nathan, Robert A ^c   Thompson, Ann K ^d  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b Nebraska Medical Research Institute   (United States)

^c Asthma & Allergy Associates PC and Research Center   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; FEXOFENADINE;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL DISABILITY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL; WORK DISABILITY;

EID: 0032697271     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62671-3     Document Type: Article

References (21)

1. Nathan RA, Meltzer EO, Seiner JC, Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:S808-814.
2. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997;99:S773-780.
3. Simons FER. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996;17:185-189.
4. Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996;98:309-316.
5. Blaiss MS. The role of outcome studies in allergy and clinical immunology. Allergy Asthma Proc 1996;17:355-358.
6. Tarnasky PR, Van Arsdel PP. Antihistamine therapy in allergic rhinitis. J Fam Pract 1990;30:71-80.
7. Bronsky EA, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist in the treatment of fall allergies. Allergy Asthma Proc 1998;19: 135-141.
8. Bernstein D, Schoenwetter W, Nathan R, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-448.
9. Tanner LA, Reilly M, Meltzer EO, et al. Effect of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Man Care 1999;5(suppl):S235-S447.
10. Allegra prescribing information. Hoechst Marion Roussel, Inc. Kansas City, MO. December, 1996.
11. Casale TB, Andrade C, Qu R. Safety and effectiveness of once-daily fexofenadine HCl in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 1999;20:193-198.
12. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83.
13. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993;4(5):353-365.
14. Reilly MC, Tanner A, Meltzer EO. Work, classroom, and activity impairment instruments. Clin Drug Invest 1996;11(5):278-288.
15. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473-483.
16. How to score the MOS 36-item short-form health survey (SF-36). SF-36 scoring rules (version 1.1). International Resource Center (IRC) for Health Care Assessment, New England Medical Center Hospitals. Copyright 1992 MOS Trust, Inc.
17. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-629.
18. 1-receptor antagonist drugs. J Allergy Clin Immunol 1996; 98:8307-318.
19. Juniper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1997;98(4):843-845.
20. Paul E, Berth-Jones J, Ortonne J-P, Stern M. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat 1998;9:143-149.
21. Russell T, Stolz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple dose fexofenadine HCl in healthy male volunteers. Clin Pharmacol Ther 1998;64: 612-621.